Press Releases REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
15.44 ^USD	-1.53%		-8.26%	-13.98%

May. 09	UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating	MT
May. 08	Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

REGENXBIO to Participate in Upcoming Investor Conferences	May. 10	PR
Regenxbio: Q1 Earnings Snapshot	May. 08	AQ
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights	May. 01	PR
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	Apr. 24	PR
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	Apr. 04	AQ
One-time gene therapy could improve wet AMD	Apr. 01	AQ
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days	Mar. 27	PR
REGENXBIO to Participate in Upcoming Investor Conferences	Mar. 11	PR
REGENXBIO Announces Proposed Public Offering of Common Stock	Mar. 07	AQ
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL	Mar. 06	AQ
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE Trial	Mar. 01	AQ
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial	Feb. 29	PR
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	Feb. 28	AQ
Regenxbio: Q4 Earnings Snapshot	Feb. 27	AQ
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	Feb. 21	PR
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint	Feb. 08	AQ
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE Trial	Feb. 08	AQ
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024	Jan. 31	PR
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery	Jan. 17	AQ
District Court Grants Summary Judgment And Invalidates Patent In REGENXBIO v. Sarepta Litigation	Jan. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases REGENXBIO Inc.

Equities

RGNX

US75901B1070

Press Releases

Filters